Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 16/20 | 0.47 |
| ▸ | GIPR | P48546 | 6/20 | 0.47 |
| ▸ | GLP1R | P43220 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660031 | 1.00 | GCGR (0.47) | GCGRGIPRGLP1RPOLBMAPT | |
| SCHEMBL4092369 | 0.87 | GCGR (0.62) | GCGRGIPRGLP1R | |
| SCHEMBL6289107 | 0.85 | GCGR (0.64) | GCGRGIPRGLP1R | |
| SCHEMBL2654825 | 0.84 | GCGR (0.53) | GCGRGIPRGLP1REPHX2 | |
| SCHEMBL6292689 | 0.82 | GCGR (0.66) | GCGRGIPRGLP1R | |
| SCHEMBL2653374 | 0.81 | GCGR (0.52) | GCGRGIPRGLP1REPHX2 | |
| SCHEMBL2653378 | 0.81 | GCGR (0.52) | GCGRGIPRGLP1REPHX2 | |
| SCHEMBL6292621 | 0.80 | GCGR (0.51) | GCGRGIPRPOLBMAPTFPR2 | |
| SCHEMBL6292620 | 0.80 | GCGR (0.51) | GCGRGIPRPOLBMAPTFPR2 | |
| SCHEMBL4088055 | 0.80 | GCGR (0.52) | GCGRGIPRGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | claimed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | claimed |
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| WO-2004063147-A1 | SALTS AND SOLVATES OF GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-07-29 | — | — | WO | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885GIPR 4/4885GLP1R 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.